Abzu elevates its position in the life sciences with a heavy profile in biotech, Mette Kirstine Agger, appointing her as a new member of their board. For the past 12 years, Mette Kirstine Agger has been part of the management team at Lundbeckfonden and Managing Partner for Lundbeckfonden Ventures, a foundation dedicated to accelerating the development of new medicines and treatments through investments in international biotech companies.
Mette Kirstine Agger will help Abzu strengthen its position in the life sciences and biotech industries by building a bridge between research and business development with her special experience in how new technologies can create and support growth and business opportunities within biotech and a wide range of other lines of industries.
“Abzu has a very special approach to how, with completely new artificial intelligence, we can make data more qualitative and create useful hypotheses that can be tested — and explain contexts and patterns. It has a huge potential across industries, and I look forward to working with my new colleagues to give scientists and researchers a better understanding and insight into data,” says Mette Kirstine Agger.
Abzu is also looking forward to the new collaboration.
“Mette has over 25 years of experience in life science, and with her in-depth knowledge in the life science industry, she will help us build a bridge between research and business development. With Mette on the team, we are further upgrading our competencies within biotech, which is an important strategic area for us in the coming years. We see exciting times ahead, both in the Danish market and internationally, ”says Casper Skern Wilstrup, co-founder and CEO of Abzu.
Abzu was founded in 2018, and today there are 27 Abzoids in offices in Copenhagen and Barcelona. Abzu has chosen to cast off traditional organizational hierarchies. Instead, Abzoids decide their own working hours and everything in the workplace is transparent, including everyone’s salaries.
Mette Kirstine Agger noticed this different way of running an organization, and she believes is a rare sight among Danish companies.
“There is sometimes more innovation and drive in a self-managing organization, and Abzu is a great example of a modern company that approaches everything in a different way. It is a culture with a focus on freedom under responsibility, diversity, and respect, and I look forward to being a part of it.”
Founded in 2018, Abzu® builds trustworthy AI to tackle complex challenges for the world’s leading companies. Abzu established itself as a global leader in explainable, rational, and safe AI in the pharmaceutical industry, contributing to new discoveries in disease understanding and RNA therapeutics. Today, Abzu’s technology accelerates new insights and understanding in pharma R&D and transforms critical and complex business processes for enterprise operations.
Abzu has offices in Copenhagen and Barcelona, and has raised €13.3M in total funding to date. Abzu has been mentioned in Gartner® research, from Market Guides for AI Trust, Risk, and Security Management to CoolVendor™, and is the winner of several awards, including the 2023 “Best HealthTech” Nordics Award at the Nordic Startup Awards. For more information, visit www.abzu.ai.
About Mette Agger.
Mette has extensive international experience in biotech and life sciences, more specifically business development and licenses, administration, and financing. Mette is currently Managing Partner for Lundbeckfonden Ventures, and has been appointed to several board positions at both private and public companies. She has previously co-founded and been CEO of 7TM Pharma A / S, and over the years has co-founded several biotech companies. Prior to founding 7TM Pharma, Mette was part of the management of NeuroSearch A / S with responsibility for business development and licenses.
She started her career as a patent agent. Mette Kirstine Agger is a biologist from the University of Copenhagen and has an MBA from Henley Business School.